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Purpose: To describe the clinical manifestations of presumed gadolinium toxicity in patients with normal
renal function.
Materials and methods: Participants were recruited from two online gadolinium toxicity support groups.
The survey was anonymous and individuals were instructed to respond to the survey only if they had
evidence of normal renal function, evidence of gadolinium in their system beyond 30 days of this MRI, and
no pre-existent clinical symptoms and/or signs of this type.
Results: 42 subjects responded to the survey (age: 28–69, mean 49.1 ± 22.4 years). The most common
ﬁndings were: central pain (n = 15), peripheral pain (n = 26), headache (n = 28), and bone pain (n =
26). Only subjects with distal leg and arm distribution described skin thickening (n = 22). Clouded
mentation and headache were the symptoms described as persistent beyond 3 months in 29 subjects.
Residual disease was present in all patients. Twenty-eight patients described symptoms following
administration of one brand of Gadolinium-Based Contrast Agent (GBCA), 21 after a single GBCA
administration and 7 after multiple GBCA administrations, including: gadopentetate dimeglumine, n = 9;
gadodiamide, n = 4; gadoversetamide, n = 4; gadobenate dimeglumine, n = 4; gadobutrol, n = 1;
gadoteridol, n = 2; and unknown, n = 4.
Conclusions: Gadolinium toxicity appears to arise following GBCA administration, which appears to
contain clinical features seen in Nephrogenic Systemic Fibrosis, but also features not observed in that
condition.
© 2016 Elsevier Inc. All rights reserved.1. Introduction
Gadolinium related toxicity has been recognized for at least
10 years, with the initially described condition being nephrogenic
systemic ﬁbrosis (NSF). NSF is a debilitating and potentially
life-threatening disease that was ﬁrst recognized in 1997 in 15
dialyzed patients and later described in 2000 [1]. Almost a decade
later, the association between the described changes and the
administration of Gadolinium-based contrast agents (GBCAs) wasUNC at Chapel Hill, CB 7510
1 919 966 9676; fax:+1 919
).,established by groups of nephrologists, initially Grobner et al. [2]
and subsequently Marckmann et al. [3]. The combination of
limiting or avoiding the use of GBCAs in subjects with advanced
renal failure and employing more stable GBCAs greatly reduced
the incidence of this disease with no new cases reported after
2009 [4].
This led many to believe that: 1) the most stable GBCAs were
extremely safe and did not cause disease, and 2) subjects with
normal renal function did not develop gadolinium related toxicity.
However, patients with normal renal function have described
severe disease that arose shortly after the administration of GBCAs
[5,6]. A ﬁrst description of a presumed toxicity related to GBCA
administration has been recently published [5]. It appears that
patients with normal renal function may exhibit severe symptom-
atology, beyond the time frame of severe acute adverse events,
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was to access patients who report severe symptomatology
following GBCA administration, to assess the various manifesta-
tions and to attempt to identify which GBCAs may be most
responsible for the disease.
2. Methods
Institutional review board approval was obtained for this Health
Insurance Portability and Accountability Act (HIPAA) – compliant
prospective study. The survey was anonymous and all participants
were recruited from online gadolinium toxicity support groups. All
participants of the survey were informed of the purpose of the
study. An electronic link to the survey was posted to a private blog
[8] (MRI-Gadolinium-Toxicity support group) that discusses
gadolinium toxicity, and a public Gadolinium Toxicity Facebook
page [9].
The survey was posted online and consisted of 18 questions that
were completed between November 21 and November 30, 2015
(Appendix A). Participants had the option to leave any question
unanswered. All responses were anonymous. For the survey,
participants were asked to conﬁrm the number of GBCA doses and
if possible, the types of GBCA received. In addition, the survey also
asked which symptoms and signs were present, how soon after
intravenous administration of the GBCAs symptoms began, and the
duration of the symptoms.
The senior author of this study separately requested anonymized
data from the leaders of the two patient advocacy groups to provide
information on the number of patients who experienced signs and/
or symptomatology following the administration of only 1 brand of
contrast agent, if this data was pre-existent in their records, and
whether symptoms arose after a single or multiple uses of the agent.
Substantial, but not complete overlap with the survey respondents
was anticipated.
Inclusion criteria were as follows: (a) subjects with normal
renal function (eGFR N60 mL/min per 1.73 m2) who experienced
severe and persistent symptoms with onset from 1 to 365 days
following GBCA administration; and (b) who had laboratory
evidence of presence of gadolinium in their body beyond 30 days
following the inciting magnetic resonance imaging (MRI) exami-
nation. Finally, direct medical examination was performed by a
physician with expertise in NSF, on three random participants, one0
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2.1. Statistical analysis
Descriptive statistics were used for demographics, number and
types of GBCAs, kidney function, tissue tests, sites and patterns of
pain and other somatic reactions and/or changes.
R, a language and environment for statistical computing
(R Core Team, Vienna, Austria), was used for all statistical
computing.
3. Results
Forty-two participants responded to this survey (27 women,
14 men; and 1 participant did not specify). Forty were Caucasian
white and 2 were Hispanic white.
One participant reported history of renal insufﬁciency. This
patient reported a remote history of renal insufﬁciency, which
preceded the incitingMRI. At the time of the incitingMRI, the patient
had normal renal function. The age of onset ranged from 28 to 69,
mean 49.1 ± 22.4 years.
Forty-one participants had evidence of gadolinium presence
beyond 1 month after exposure. Gadolinium was documented in
urine in 41 participants and thyroid tissue in a single patient.
Elevated gadolinium in blood was seen in 8 subjects, and in other
tissues in 5 subjects, including thyroid (n = 1), scalp (n = 1), skin
(n = 2) and hair (n = 2).
Among the 42 subjects, 28 described symptoms following
administration of one brand of GBCA (Fig. 1). Twenty-one subjects
stated the symptomatology started after a ﬁrst-time administration
[gadopentetate dimeglumine (Magnevist®; Bayer HealthCare Phar-
maceuticals, Wayne, New Jersey), n = 7; gadodiamide (Omniscan®;
GE Healthcare, Piscataway, New Jersey, n = 3; gadobenate dime-
glumine (MultiHance®; Bracco Diagnostics, Princeton, New Jersey),
n = 3; gadoversetamide (OptiMARK ®; Mallinckrodt, St. Louis,
Missouri), n = 3; gadobutrol (Gadavist®; Bayer Schering Pharma,
Berlin, Germany), n = 1; Unknown, n = 4]. The remaining seven
subjects received multiple doses of a single agent [Magnevist®, n = 2;
Omniscan®, n = 1; MultiHance®, n = 1; OptiMARK®, n = 1;
gadoteridol (ProHance®; Bracco Diagnostics), n = 2]. The remain-
ing subjects had symptoms after multiple GBCAs exposures with
different agents.
The separate inquiry of the leaders of the twomajor patient advocacy
groups revealed that in the database of their members, 24 subjects
developed unconfounded cases of disease related with the administra-
tion of a single GBCA. Seventeen subjects described symptomatology
following one administration (Magnevist®, n = 6; Omniscan®, n = 3;
MultiHance®, n = 4; Optimark®, n = 4). Seven subjects received
multiple doses of only one agent (Magnevist®, n = 2; Omniscan®,
n = 1; MultiHance®, n = 2; ProHance®, n = 2).
3.1. Pain
Among the 42 subjects, pain lasted for less than 3 months,
including: central pain (n = 6), peripheral pain (n = 9), headache
(n = 4), bone pain (n = 7) and other site (n = 9). Pain lasted
beyond 3 months, and persisted to the time of the survey,
including: central pain (n = 15), peripheral pain (n = 26),
headache (n = 28) and bone pain (n = 26) and other pain
location (n = 25) (Fig. 2). Often the same patient described
more than one type of pain.
Pain at presentation was described as sharp pain/“pins and
needle” in 25 subjects (15 central, 10 peripheral) and intense
burning in 15 (10 central, 5 peripheral). The distribution of pain
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In 10 patients who suffer from peripheral leg and arm pain
from the start, the character of pain changed to an intense burning
in all patients.
3.2. Skin changes
Tissue thickening arose from 2 weeks to 2 months following
GBCA administration. Only subjects with distal leg and arm
distribution described skin thickening (n = 22), which was
conﬁned to the distribution of the pain. Skin discoloration was
seen in 28 subjects (Fig. 2).
3.3. Musculoskeletal manifestations
Bone pain was present in 33 subjects. Joint stiffness was present
in 33 subjects, muscle spams in 30 subjects, buzzing sensation in
24 subjects, fatigue in 36 subjects and skin edema in 22 subjects
(Fig. 2).
3.4. Central neurological ﬁndings
Clouded mentation was a symptom described as persistent
beyond 3 months in 29 subjects (all of whom also had headache).
Metallic taste was reported in 19 subjects as a prominent persistent
metallic taste following the inciting gadolinium administration.Single Injection Multiple Injections
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Fig. 2. Graphic representation of the symptoms occurrence rate in early (b3 months) an
manifestations (C) and additional symptoms (D).This taste arose immediately to 1 day following the administration
and persisted for up to or more than one month.
3.5. Persistence of disease
In all subjects (n = 42) residual disease, symptoms were noted
to diminish over time (ranging from 4 months to 8 years), but
continued to interfere with daily life. These patients suffer from skin
thickening (n = 29) (self-characterized as rubbery or spongy skin
thickening of the ﬁngers in 20 subjects), andmoderate pain. Residual
pain was observed in 31 subjects.
All 42 subjects responded that they possessed the symptoms
requested on the survey, and additional 37 subjects added additional
persisting symptoms (Fig. 3).
4. Discussion
Our results show that many of the respondents' reported signs
and symptoms are consistent among subjects, and include various
ﬁndings similar, but less severe than found in NSF [10]. Based on
these results, we propose a name for this presumed disease process
in subjects with normal renal function and gadolinium toxicity,
Gadolinium Deposition Disease (GDD). At least 60% of our subjects
showed a glove-and-sock distribution of disease associated with
intense sharp “pins and needles” or burning pain, and skin changes,
resembling NSF [11–13]. Other examples of similar but less severe
changes compared to NSF include: tissue in NSF is often describedSingle Injection Multiple Injections
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Fig. 3. Graphic representation of the occurrence rate of persistent symptoms (symptom
occurring up to the day of the survey).
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sas woody and joint contractions severe, whereas subjects in our
survey have reported as spongy or rubbery, and joint ﬂexures
minimal. Fifteen subjects (35%) reportedly exhibited persistent
central torso (trunk) pain and 22 (52%) patients reported distal leg
and arm pain along tissue thickening also comparable with NSF. A
2011 report of gadolinium presence in tissues in subjects with NSF,
described two control groups of subjects with normal renal
function, and previous GBCA administration, who also demon-
strated gadolinium in their tissue samples [14].
Bone pain was a commonly reported ﬁnding in our survey.
Intense headache and clouded mentation were commonly report-
ed also. This feature appears more distinctive for this presumed
GDD, as this has not been generalized recognized in the NSF
population.
It is not unreasonable that physicians may be skeptical that
subjects with normal renal function may develop toxic disease to
gadolinium. Sieber et al. [15] reported on the occurrence of NSF-like
skin condition development in the rat model with normal renal
function studyingmultiple GBCAs, who received large doses of agent.
In the clinical setting, many humans have also undergone multiple
serial examinations with GBCA, which is not uncommon for some
disease processes (e.g. Multiple Sclerosis patients), recreating the
circumstance of this animal study. A case report of this type has been
recently reported in which the subject had received 61 administra-
tions of GBCA [16]. This case report challenged published literature,
suggesting that in patients with normal renal function, exposure to
GBCAs in extremely high cumulative doses can lead to signiﬁcant
gadolinium deposition in the skin. Interestingly this patient had no
history of skin disorders and did not have a history of nephrogenic
systemic ﬁbrosis but did have severe joint contractures of unknown
etiology.
In reviewing the agents the suspected causative GBCAs whose
unconfounded use resulted in reported symptoms, were also
those more related to NSF, in 83% from our survey data and 75%
from the data provided by the patient action groups. However,
some individuals also reportedly developed this disease following
MultiHance®, a linear agent with intermediate stability [17], but
also after macrocyclic agents, which are the most stable. In this
survey, the only agent that was not associated with presumed
toxicity was Dotarem®. It should however be acknowledged that
Dotarem® is the most recently FDA-approved GBCA and hasprobably the lowest number of doses administered in the USA,
where our data is acquired from.
It may be that a greater range of immune system elements may
be activated in this normal renal function group compared to renal
failure patients who develop NSF. It is possible that the polypeptides
that result in acute adverse events form a critical component of the
entire immune response to these agents, in addition to the later
cell-based immune response, described with CD34+ ﬁbroblasts in
NSF [18]. This hypothesis relies on the observation that all GBCAs,
regardless of stability, elicit acute adverse events [19]. Along this line
of explanation, Wermuth et al. [20] found that both linear and
macrocyclic agents stimulated release of numerous chemokines,
cytokines, and growth factors, which are mediators of acute
reactions.
Based on this survey we believe the critical ﬁndings are the
presence of gadolinium in the body, which we randomly chose
beyond 30 days, combined with at least 3 of the following features,
that must have shown onset only after the administration of GBCA: i)
central torso pain, ii) headache and clouded mentation, iii)
peripheral leg and arm pain, iv) peripheral leg and arm thickening
and discoloration, and v) bone pain.
Based on the veracity of this survey that subjects with normal
renal function may develop severe disease following administration
of GBCAs, is on the surface very worrisome. It should however be
noted that at present the number of subjects with this severe
reaction may be relatively few and may have a low occurrence rate,
comparable to that of catastrophic acute adverse reactions for
gadolinium- and iodine-based contrast agents [19,21–23].
There are various limitations of our study. Major problems
include that it is a survey and relies on knowledge and integrity of
the respondents. Despite that a survey provides all the participants
with a standardized stimulus, eliminating researcher's own biases,
it is recognized that self-report studies may have validity
problems. Although the study is subjective, in that we rely on
patient descriptions, it should also be appreciated that there was a
generally common pattern of symptomatology. A control group of
subjects who received multiple administrations of GBCAs, but who
do not have symptoms would be helpful. As an anonymous survey
with predeﬁned questions, we neither asked nor had access to the
clinical indications for the MR examinations. It should be stressed
that our survey emphasized that the clinical ﬁndings they
attribute to gadolinium toxicity must be new ﬁndings that were
not present prior to contrast administration. Moreover, no patient
took medications other than GBCAs that could be possible causes
for the reported signs and symptoms.
Skin histology was also not evaluated, which would also be of
interest. A recent report by Gathings et al. [24] described
histologic features of a new condition that they observed in
patients with normal renal function, that they called Gadolinium-
Associated Plaques. These were erythematous plaques containing
sclerotic bodies in the skin following GBCA administrations that
previously were thought to be pathognomonic for NSF. It would
be interesting to learn if these patients were symptomatic.
Finally, our hypothesis that GDD combines both acute and
chronic immune mechanisms has not been conﬁrmed histolog-
ically or biochemically.
In summary, we report a presumed GBCA toxicity in patients
with normal renal function, that we term GDD. These patients
reportedly experienced severe and persistent symptoms that
might resemble a milder form of NSF, but may also possess some
distinct features. In this survey the weakest chelates were the
agents most likely to cause this reported toxicity, but more stable
agents were also implicated in it. In the very least our study
emphasizes that further prospective investigation is needed to
verify this condition.
Appendix A. Survey
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